| Hazard Information | Back Directory | [Uses]
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model[1]. | [in vivo]
Ogalvibart (C-135-LS; 10 mg/kg; 75 days before infection) in combination with 10 mg/kg C144LS can effectively block development of COVID-19 in the rhesus disease model[1]. | Animal Model: | Rhesus macaques (3-11 years old)[1]. | | Dosage: | 10 mg/kg (in combination with 10 mg/kg C144LS) | | Administration: | 75 days before infection | | Result: | Protected a subset of animals whose infectious challenge was 75 days post administration from disease. |
| [References]
[1] Beddingfield BJ, et al. Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. Front Cell Infect Microbiol. 2021 Nov 18;11:753444. DOI:10.3389/fcimb.2021.753444 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|